Literature DB >> 21446024

N-acetylcysteine prevents loss of dopaminergic neurons in the EAAC1-/- mouse.

Ari E Berman1, Wai Yee Chan, Angela M Brennan, Reno C Reyes, Brittany L Adler, Sang Won Suh, Tiina M Kauppinen, Ylva Edling, Raymond A Swanson.   

Abstract

OBJECTIVE: Dopaminergic neuronal death in Parkinson's disease (PD) is accompanied by oxidative stress and preceded by glutathione depletion. The development of disease-modifying therapies for PD has been hindered by a paucity of animal models that mimic these features and demonstrate an age-related progression. The EAAC1(-/-) mouse may be useful in this regard, because EAAC1(-/-) mouse neurons have impaired neuronal cysteine uptake, resulting in reduced neuronal glutathione content and chronic oxidative stress. Here we aimed to (1) characterize the age-related changes in nigral dopaminergic neurons in the EAAC1(-/-) mouse, and (2) use the EAAC1(-/-) mouse to evaluate N-acetylcysteine, a membrane-permeable cysteine pro-drug, as a potential disease-modifying intervention for PD.
METHODS: Wild-type mice, EAAC1(-/-) mice, and EAAC1(-/-) mice chronically treated with N-acetylcysteine were evaluated at serial time points for evidence of oxidative stress, dopaminergic cell death, and motor abnormalities.
RESULTS: EAAC1(-/-) mice showed age-dependent loss of dopaminergic neurons in the substantia nigra pars compacta, with more than 40% of these neurons lost by age 12 months. This neuronal loss was accompanied by increased nitrotyrosine formation, nitrosylated α-synuclein, and microglial activation. These changes were substantially reduced in mice that received N-acetylcysteine.
INTERPRETATION: These findings suggest that the EAAC1(-/-) mouse may be a useful model of the chronic neuronal oxidative stress that occurs in PD. The salutary effects of N-acetylcysteine in this mouse model provide an impetus for clinical evaluation of glutathione repletion in PD.
Copyright © 2010 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21446024      PMCID: PMC4096233          DOI: 10.1002/ana.22162

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  48 in total

1.  Modulation of the neuronal glutamate transporter EAAC1 by the interacting protein GTRAP3-18.

Authors:  C I Lin; I Orlov; A M Ruggiero; M Dykes-Hoberg; A Lee; M Jackson; J D Rothstein
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

Review 2.  Neuropathology of synuclein aggregates.

Authors:  J E Duda; V M Lee; J Q Trojanowski
Journal:  J Neurosci Res       Date:  2000-07-15       Impact factor: 4.164

3.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease.

Authors:  R Betarbet; T B Sherer; G MacKenzie; M Garcia-Osuna; A V Panov; J T Greenamyre
Journal:  Nat Neurosci       Date:  2000-12       Impact factor: 24.884

Review 4.  Metabolism and functions of glutathione in brain.

Authors:  R Dringen
Journal:  Prog Neurobiol       Date:  2000-12       Impact factor: 11.685

Review 5.  Animal models of Parkinson's disease.

Authors:  Ranjita Betarbet; Todd B Sherer; J Timothy Greenamyre
Journal:  Bioessays       Date:  2002-04       Impact factor: 4.345

6.  The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice.

Authors:  Susan A Farr; H Fai Poon; Dilek Dogrukol-Ak; Jeniffer Drake; William A Banks; Edward Eyerman; D Allan Butterfield; John E Morley
Journal:  J Neurochem       Date:  2003-03       Impact factor: 5.372

7.  Role of neuronal glutamate transporter in the cysteine uptake and intracellular glutathione levels in cultured cortical neurons.

Authors:  T Himi; M Ikeda; T Yasuhara; M Nishida; I Morita
Journal:  J Neural Transm (Vienna)       Date:  2003-10-24       Impact factor: 3.575

8.  Glial soluble factors regulate the activity and expression of the neuronal glutamate transporter EAAC1: implication of cholesterol.

Authors:  B Canolle; F Masmejean; C Melon; A Nieoullon; P Pisano; S Lortet
Journal:  J Neurochem       Date:  2004-03       Impact factor: 5.372

9.  Cysteine/cystine couple is a newly recognized node in the circuitry for biologic redox signaling and control.

Authors:  Dean P Jones; Young-Mi Go; Corinna L Anderson; Thomas R Ziegler; Joseph M Kinkade; Ward G Kirlin
Journal:  FASEB J       Date:  2004-06-04       Impact factor: 5.191

10.  A neuronal glutamate transporter contributes to neurotransmitter GABA synthesis and epilepsy.

Authors:  Jehuda P Sepkuty; Akiva S Cohen; Christine Eccles; Azhar Rafiq; Kevin Behar; Raquelli Ganel; Douglas A Coulter; Jeffrey D Rothstein
Journal:  J Neurosci       Date:  2002-08-01       Impact factor: 6.167

View more
  63 in total

1.  Investigation of the therapeutic potential of N-acetyl cysteine and the tools used to define nigrostriatal degeneration in vivo.

Authors:  Negin Nouraei; Lauren Zarger; Justin N Weilnau; Jimin Han; Daniel M Mason; Rehana K Leak
Journal:  Toxicol Appl Pharmacol       Date:  2016-02-12       Impact factor: 4.219

2.  Characterizing N-acetylcysteine (NAC) and N-acetylcysteine amide (NACA) binding for lead poisoning treatment.

Authors:  Weiqing Chen; Nuran Ercal; Tien Huynh; Anatoliy Volkov; Charles C Chusuei
Journal:  J Colloid Interface Sci       Date:  2011-12-27       Impact factor: 8.128

3.  The density of EAAC1 (EAAT3) glutamate transporters expressed by neurons in the mammalian CNS.

Authors:  Silvia Holmseth; Yvette Dehnes; Yanhua H Huang; Virginie V Follin-Arbelet; Nina J Grutle; Maria N Mylonakou; Celine Plachez; Yun Zhou; David N Furness; Dwight E Bergles; Knut P Lehre; Niels C Danbolt
Journal:  J Neurosci       Date:  2012-04-25       Impact factor: 6.167

Review 4.  Neurobiology of obsessive-compulsive disorder: insights into neural circuitry dysfunction through mouse genetics.

Authors:  Jonathan T Ting; Guoping Feng
Journal:  Curr Opin Neurobiol       Date:  2011-05-24       Impact factor: 6.627

Review 5.  Cellular Timekeeping: It's Redox o'Clock.

Authors:  Nikolay B Milev; Sue-Goo Rhee; Akhilesh B Reddy
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

6.  OCD candidate gene SLC1A1/EAAT3 impacts basal ganglia-mediated activity and stereotypic behavior.

Authors:  Isaac D Zike; Muhammad O Chohan; Jared M Kopelman; Emily N Krasnow; Daniel Flicker; Katherine M Nautiyal; Michael Bubser; Christoph Kellendonk; Carrie K Jones; Gregg Stanwood; Kenji Fransis Tanaka; Holly Moore; Susanne E Ahmari; Jeremy Veenstra-VanderWeele
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-15       Impact factor: 11.205

7.  Nanomicellar formulation of coenzyme Q10 (Ubisol-Q10) effectively blocks ongoing neurodegeneration in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model: potential use as an adjuvant treatment in Parkinson's disease.

Authors:  Marianna Sikorska; Patricia Lanthier; Harvey Miller; Melissa Beyers; Caroline Sodja; Bogdan Zurakowski; Sandhya Gangaraju; Siyaram Pandey; Jagdeep K Sandhu
Journal:  Neurobiol Aging       Date:  2014-04-02       Impact factor: 4.673

Review 8.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

9.  Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid.

Authors:  Reno C Reyes; Giordano Fabricio Cittolin-Santos; Ji-Eun Kim; Seok Joon Won; Angela M Brennan-Minnella; Maya Katz; Graham A Glass; Raymond A Swanson
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

10.  Hypoxia-inducible factor 1 contributes to N-acetylcysteine's protection in stroke.

Authors:  Ziyan Zhang; Jingqi Yan; Saeid Taheri; Ke Jian Liu; Honglian Shi
Journal:  Free Radic Biol Med       Date:  2013-12-01       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.